Doctors expect to prescribe Sarepta’s DMD drug despite insurance concerns
(By Ed Silverman for STAT) Definitive proof may be lacking that the newly approved1 Duchenne muscular dystrophy actually works, but
Read More
Part D/Prescription Drugs
Novel cancer treatment from Kite Pharma notches positive results, but big questions remain
(By Damian Garde for STAT) A promising new approach to cancer is moving closer to reaching patients, as the biotech company Kite
Read MoreDiabetes drugs are badly needed, but rarely make it to market
(By Ed Silverman for STAT) Diabetes 1may be a widespread disease for which millions of people need treatment, but a
Read MoreThe world’s best-selling drug is in line for cheaper competition — eventually
(By Damian Garde for STAT) The Food and Drug Administration on Friday approved a lower-cost version of the world’s top-selling
Read MoreWhy Pharmaceutical Companies Like Mylan Charge So Much for Drugs
(By Melissa Quinn for The Daily Signal) In the wake of news that pharmaceutical company Mylan quadrupled the price of
Read MoreFreeze-dried drug factories could make a slew of medicines — just add water
(By Eric Boodman for STAT) The contraption looks and sounds like a washing machine: a rumbling box with a circular
Read MoreThe curious case of the $9,500 skin gel
(By Ed Silverman for STAT) Even in an age when prescription drugs are increasingly expensive, a $9,500 tube of gel
Read MoreIt’s time to call the opioid epidemic a public health emergency
(By Benjamin Bearnot & Mark Eisenberg for STAT) Last month, the Obama administration declared a public health emergenc1y in Puerto
Read MoreThe drug industry might finally have an answer for migraines
(By Damian Garde for STAT) It often starts with the aura. Zig-zagging lines come into view, everyday light becomes searingly
Read MoreChanges to UnitedHealth Drug Formulary List Includes Biosimilar Drugs
On Wednesday, UnitedHealth announced their proposed changes to their drug formulary list which include excluding Sanofi’s insulin Lantus and Amgen’s
Read More